Breaking News Instant updates and real-time market news.

NFLX

Netflix

$195.86

0.91 (0.47%)

, SNAP

Snap

$16.55

0.57 (3.57%)

07:35
10/13/17
10/13
07:35
10/13/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Netflix (NFLX), Snap Inc. (SNAP), Applied Materials (AMAT), J C Penney (JCP), Viacom (VIAB), Rio Tinto (RIO), Harley Davidson (HOG), LendingClub (LC), Global Blood Therapeutics (GBT), and Genesis Energy (GEL).

NFLX

Netflix

$195.86

0.91 (0.47%)

SNAP

Snap

$16.55

0.57 (3.57%)

AMAT

Applied Materials

$53.31

0.08 (0.15%)

JCP

J.C. Penney

$3.35

-0.13 (-3.74%)

VIAB

Viacom

$24.57

-0.64 (-2.54%)

RIO

Rio Tinto

$48.08

0.33 (0.69%)

HOG

Harley-Davidson

$46.46

0.19 (0.41%)

LC

LendingClub

$6.35

-0.05 (-0.78%)

GBT

Global Blood Therapeutics

$32.95

-0.25 (-0.75%)

GEL

Genesis Energy

$25.14

-1.24 (-4.70%)

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Dec

NFLX Netflix
$195.86

0.91 (0.47%)

10/12/17
GSCO
10/12/17
NO CHANGE
GSCO
Goldman Sachs Tactical Trades ahead of earnings
Goldman analysts led by John Marshall highlight some of the firm's most out-of-consensus opportunities ahead of the earnings season. The firm sees potential for upward earnings revisions to drive share upside in Caterpillar (CAT), ENGlobal (ENTG), McDonald's, (MCD) and Netflix (NFLX) and downwards earnings revisions to drive downside in Grainger (GWW), Cree (CREE), and Tesla (TSLA).
10/12/17
BERN
10/12/17
NO CHANGE
Target $230
BERN
Outperform
Netflix price target raised to $230 from $203 at Bernstein
Bernstein analyst Todd Juenger raised his price target for Netflix to $230 from $203 after the company announced a price increase last week impacting subscribers in the U.S. and several major European countries as well. The analyst reiterates an Outperform rating on the shares.
10/13/17
JPMS
10/13/17
NO CHANGE
Target $225
JPMS
Overweight
Netflix price target raised to $225 from $210 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Netflix (NFLX) shares to $225 ahead of the company's Q3 results on Monday, October 16. The analyst cites the recent price increase as well as the T-Mobile (TMUS) promotion for his higher target. He upped his estimate for Q3 U.S. net subscriber additions to 800,000 from 765,000 but lowered his Q4 estimate to 1.65M from 1.7M as he expects price increase-related churn to potentially offset the T-Mobile promotion. Netflix remains one of Anmuth's top two large-cap picks.
10/13/17
SBSH
10/13/17
NO CHANGE
Target $205
SBSH
Neutral
Netflix price target raised to $205 from $180 at Citi
Citi analyst Mark May raised his price target for Netflix shares to $205 while keeping a Neutral rating on the name. The recently announced price increases are necessary to address the investment in content and related cash burn, but also reflect the company's pricing power, May tells investors in a research note. The analyst, however, believes the shares at current levels largely price in long-term bull-case assumptions.
SNAP Snap
$16.55

0.57 (3.57%)

09/25/17
JPMS
09/25/17
NO CHANGE
Target $14
JPMS
Neutral
Snap price target lowered to $14 from $16 at JPMorgan
JPMorgan analyst Doug Anmuth lowered his estimates for Snap citing the transition to self-serve, tougher comps in the second half of 2017 and "mixed sentiment" from his firm's channel checks with advertiser. Snap's ad monetization is likely taking longer than expected, Anmuth tells investors in a research note. He cut his price target for the shares to $14 and keeps a Neutral rating on Snap.
10/05/17
NEED
10/05/17
NO CHANGE
NEED
Underperform
Needham advises caution on Snap, sees 10%-20% near-term downside
Needham analyst Laura Martin notes that Snap's shares have generally bounced between $13-$15 since August 1, 2017. The analyst advises caution as she sees 10%-20% near-term downside, based on fundamental weakness. Further, Martin lowered her Snap estimates for FY17, FY18, and FY19 based on her channel checks, while noting the company continues to have trouble proving out ROI to brands because Snap is more of a "top of funnel" ad platform. She reiterates an Underperform rating on the shares.
10/10/17
LEHM
10/10/17
NO CHANGE
Target $13
LEHM
Equal Weight
Barclays 'warming up a little' on the Snap story
Barclays analyst Ross Sandler says that while he remains on the sidelines into Snap's Q3 earnings report, he's "warming up a little on the story." The shares are not likely to trade meaningfully higher until the company can demonstrate consistent upside to consensus, Sandler tells investors in a pre-earnings research note. He thinks this will not happen until next quarter at the earliest. The analyst's channel checks, however, suggest continued improvement in the ad stack, including good reception to the lower auction prices for Snap Ads. Sandler recommends letting this quarter play out before considering adding to a position. The analyst keeps an Equal Weight rating on Snap with a $13 price target.
10/11/17
FBCO
10/11/17
NO CHANGE
Target $20
FBCO
Outperform
Snap price target raised to $20 ahead of results at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Snap to $20 from $17 ahead of Q3 earnings results as he modestly increases his North American DAU estimates and rolls forward his valuation parameters to end-of-2018. The analyst reiterates an Outperform rating on the shares.
AMAT Applied Materials
$53.31

0.08 (0.15%)

10/12/17
DADA
10/12/17
NO CHANGE
Target $215
DADA
Buy
Lam Research price target raised to $215 from $200 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Lam Research (LRCX) to $215 to reflect expectations of a ramp up in activity at the end of this year. Diffely says the near-term industry drivers - 3D NAND and Foundry - were summed up by the recent Applied Materials (AMAT) analyst meeting and bode well for Lam Research in Q4 and through the first half of FY18. Diffely kept his Buy rating on Lam Research.
10/12/17
DBAB
10/12/17
NO CHANGE
Target $58
DBAB
Buy
Applied Materials price target raised to $58 from $52 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his estimates for Applied Materials and upped his price target for the shares to $58 citing a "stronger and more sustainable" WFE environment as well as better growth prospects for the Services and Display businesses. New demand from artificial intelligence and autonomous driving are creating the for more advanced logic and memory, leading to more sustainable growth, Ho tells investors in a research note. He also believes the "strong" build-out of OLED and Gen-10.5 LCD will extend the strength of the current display cycle. The analyst reiterates a Buy rating on shares of Applied Materials.
09/28/17
CHLM
09/28/17
NO CHANGE
Target $76
CHLM
Buy
Applied Materials price target raised to $76 from $60 at Craig-Hallum
Craig-Hallum analyst Christian Schwab raised his price target for Applied Materials to $76 from $60 after management introduced a new FY20 EPS target of $5.08. The analyst reiterates a Buy rating on the shares.
09/28/17
MSCO
09/28/17
NO CHANGE
Target $56
MSCO
Overweight
Applied Materials long term guidance better than expected, says Morgan Stanley
Morgan Stanley analyst Joseph Moore said Applied Materials' analyst meeting was an "even stronger catalyst than we had hoped," noting that the company raised its 2020 targets "well beyond" his expectations driven by upside for display, services, share repurchases and taxes. Moore keeps an Overweight rating and $56 price target on Applied Materials shares.
JCP J.C. Penney
$3.35

-0.13 (-3.74%)

08/11/17
FBCO
08/11/17
NO CHANGE
FBCO
Underperform
J.C. Penney core operating profitability declining, says Credit Suisse
Credit Suisse analyst Christian Buss, in a research bulletin issued on the heels of J.C. Penney's Q2 report, said "continued caution is in order" as he sees it core operating profitability declining and underlying demand still being "tepid." He has an Underperform rating on J.C. Penney shares, which are down 23% in pre-market trading.
08/11/17
TLSY
08/11/17
DOWNGRADE
TLSY
Market Perform
J.C. Penney downgraded to Market Perform from Outperform at Telsey Advisory
08/11/17
EVER
08/11/17
NO CHANGE
EVER
J.C. Penney turnaround efforts 'just not working,' says Evercore ISI
Evercore ISI analyst Omar Saad said he is liquidating the 1.3% J.C. Penney Long Position initiated in the firm's Model Portfolio in April with the stock down 30% during that time. While acknowledging he "may be pulling the plug at the bottom," he said the company is doing everything in its power to keep its turnaround on track but efforts just are not working. Asset sales are not a sustainable long-term solution and cost-cutting initiatives are beginning to take a toll on operations, as evidenced by the jump in shrinkage that may be linked to understaffing, said Saad.
08/14/17
NRCS
08/14/17
NO CHANGE
Target $9
NRCS
Buy
J.C. Penney gross margin pressures abate in second half, says Northcoast
Northcoast analyst Kara Szafraniec said J.C. Penney shares reacted severely to the Q2 gross margin disappointment, driven largely by the closing of 127 stores. The analyst believes the liquidation of the stores was the right move and management's commentary on the go-forward business was largely encouraging. J.C. Penny's growth categories continue to outpace the chain average and the company remains positioned to defend itself in the current weak apparel environment, Szafraniec wrote. He believes the gross margin pressures will abate in the second half and reiterates his Buy rating and $9 price target.
VIAB Viacom
$24.57

-0.64 (-2.54%)

10/12/17
GUGG
10/12/17
DOWNGRADE
Target $25
GUGG
Neutral
Guggenheim sees downward fee revisions, cuts Viacom to Neutral
Guggenheim analyst Michael Morris downgraded Viacom (VIAB) to Neutral from Buy and cut his price target for the shares to $25 from $37. The analyst has "increased caution" on the company's ability to meet investor expectations for affiliate and advertising revenue growth in the coming years. Viacom's networks are at risk of downward fee revisions or carriage loss as distributors seek to mitigate cost pressures, Morris tells investors in a research note. The analyst expects total revenue for the pay-TV ecosystem to come under pressure.
10/12/17
10/12/17
DOWNGRADE
Target $105

Neutral
Disney downgraded to Neutral on increased pay-TV caution at Guggenheim
As previously reported, Guggenheim analyst Michael Morris downgraded Disney (DIS) to Neutral from Buy, citing his increased caution toward pay-TV trends and concern that expectations for the contribution from its content cycle are too high. While he is optimistic about the company's proposed direct-to-consumer streaming products, he expects the initial investment and long lead time into the launch to weigh on sentiment over the next 12 months, Morris tells investors. The analyst, who lowered his price target on Disney to $105 from $122, also downgraded Viacom (VIAB) and AMC Networks (AMCX) this morning.
10/12/17
GUGG
10/12/17
DOWNGRADE
GUGG
Neutral
Viacom downgraded to Neutral from Buy at Guggenheim
10/12/17
10/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Matthew Fassler saying shares have achieved in three months what he had expected in a year on an improvement in sentiment, but not on higher earnings estimates. 2. Monro (MNRO) downgraded to Hold from Buy at Jefferies with analyst Bret Jordan citing expectations the company's earnings growth will slow in 2018 as its focus shifts from acquisitions to improving store-level execution. 3. Diamond Offshore (DO) downgraded to Sell from Neutral at Citi with analyst Scott Gruber saying that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 4. Cummins (CMI) downgraded to Neutral following dealer checks at Longbow with analyst Faheem Sabeiha citing a recent truck dealer survey that suggests initial 2018 sales growth is below current industry forecasts, partly due to driver shortage concerns. 5. Disney (DIS), AMC Networks (AMCX), and Viacom (VIA, VIAB) were downgraded to Neutral from Buy at Guggenheim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RIO Rio Tinto
$48.08

0.33 (0.69%)

09/26/17
ADAM
09/26/17
DOWNGRADE
ADAM
Hold
Rio Tinto downgraded to Hold from Buy at Canaccord
08/15/17
RBCM
08/15/17
DOWNGRADE
RBCM
Outperform
Rio Tinto downgraded to Outperform from Top Pick at RBC Capital
08/15/17
RBCM
08/15/17
DOWNGRADE
RBCM
Outperform
Rio Tinto downgraded at RBC Capital
As noted earlier, RBC Capital downgraded Rio Tinto to Outperform from Top Pick. Analyst Tyler Broda downgraded the stock after the company announced a higher than expected dividend/buyback initiative, saying that he had become more upbeat on Anglo American and Glencore relative to Rio Tinto.
05/17/17
RBCM
05/17/17
UPGRADE
RBCM
Top Pick
Rio Tinto upgraded to Top Pick from Outperform at RBC Capital
RBC Capital analyst Tyler Broda upgraded Rio Tinto to Top Pick following the recent pullback in shares. The analyst believes the market is taking too negative a view on the medium-term iron ore market and not the low cost, high free cash flow story.
HOG Harley-Davidson
$46.46

0.19 (0.41%)

09/08/17
BMOC
09/08/17
NO CHANGE
BMOC
Dealers upbeat on new Harley-Davidson platform, says BMO Capital
BMO Capital analyst Gerrick Johnson reports that "core riders" have criticized Harley-Davidson's new Softail platform. However, he adds that "dealers who have ridden the new cruisers are highly complementary and believe skeptics will quickly be won over after a test ride." The analyst also reports that dealers "are hopeful that the changes" could attract younger customers. He keeps a $56 price target and an Outperform rating on the stock.
10/10/17
STFL
10/10/17
NO CHANGE
Target $48
STFL
Hold
Stifel sees risk to Harley-Davidson 2017 shipment guidance
Stifel analyst Drew Crum said that Based on checks with Harley-Davidson dealers he assumes U.S. retail sales were down by "at least low single-digits" in Q3 and he sees modest risk to the company's 2017 shipment guidance. The analyst, who keeps a Hold rating on the shares ahead of the company's report on October 17, trimmed his price target on Harley shares to $48 from $51.
10/06/17
WEDB
10/06/17
NO CHANGE
Target $45
WEDB
Neutral
Harley-Davidson checks point to weak Q3 registrations, says Wedbush
Wedbush analyst James Hardiman said his checks with U.S. Harley-Davidson dealers pointed to Q3 registrations being down about 6%, adding that feedback on the new MY18 bikes was "very much mixed." The analyst keeps a Neutral rating and $45 price target on Harley-Davidson shares.
09/13/17
UBSW
09/13/17
NO CHANGE
Target $47
UBSW
Neutral
Harley-Davidson U.S. retail sales continue to decline, says UBS
UBS analyst Robin Farley said she believes U.S. retail sales continue to decline at Harley Davidson even with easier comps in July and August. She said year-over-year comps get tougher in September and again into Q4, but the hurricanes could mask what real demand looks like. Farley reiterated her Neutral rating and $47 price target on Harley Davidson shares.
LC LendingClub
$6.35

-0.05 (-0.78%)

10/10/17
CHLM
10/10/17
NO CHANGE
CHLM
Green Dot, CPI Card added to Favorite Near-Term Risk/Reward List at Craig-Hallum
Craig-Hallum analyst Brad Berning added Green Dot (GDOT) and CPI Card Group (PMTS) to his Favorite Near-Term Risk/Reward List, saying he expects the former's positive momentum and estimate revisions to continue while believing the current quarter and 4Q outlook can be a positive catalyst for the latter. The analyst also sees positive near-term catalysts for Blackhawk (HAWK), LendingClub (LC), Verifone (PAY) and BofI Holding (BOFI).
08/21/17
CHLM
08/21/17
NO CHANGE
CHLM
Vantiv, PayPal could be $100 stocks by 2020, says Craig-Hallum
Craig-Hallum analyst Brad Berning notes that PayPal (PYPL) and Vantiv (VNTV) are two different business models that are both winning market share within the global secular growth of payments converting to digital from cash and check. The analyst believes both companies could be $100 stocks by 2020. Berning is also adding Blackhawk (HAWK) to his near-term risk/reward list, removing Vantiv and keeping PayPal, LendingClub (LC) and BofI Holding (BOFI).
08/03/17
08/03/17
UPGRADE
Target $7

Outperform
LendingClub upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Jed Kelly upgraded LendingClub to Outperform from Perform, with a $7 price target, as he believes it is creating a sticker investor base through a higher Bank/Retail mix, while utilizing its strong balance sheet to develop a potentially large securitization channel.
08/15/17
WEDB
08/15/17
NO CHANGE
WEDB
LendingClub price target raised to $5.50 from $5 at Wedbush
Wedbush analyst Henry Coffey says that Lending Club "has worked through the challenges it faced a year ago." The analyst says that the company "can grow originations 10%-15% annually and start producing traditional GAAP profits over time." He raised his price target on the shares to $5.50 from $5 and keeps a Neutral rating on the stock.
GBT Global Blood Therapeutics
$32.95

-0.25 (-0.75%)

04/17/17
RHCO
04/17/17
INITIATION
Target $56
RHCO
Buy
Global Blood Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Yatin Suneja initiated Global Blood Therapeutics with a Buy and a $56 price target saying its only clinical candidate, GBT440, has produced promising Phase I/II data in sickle cell disease. Sunna is optimistic for success in the ongoing Phase III HOPE trial, with initial data expected in late 2017/early 2018. If approved, he believes GBT440 could become the first drug to address the underlying cause of disease and achieve greater than $2B in peak sales.
09/20/17
NEED
09/20/17
INITIATION
Target $51
NEED
Buy
Global Blood Therapeutics initiated with a Buy at Needham
Needham analyst Danielle Brill initiated Global Blood Therapeutics with a Buy and a $51 price target.
08/03/17
OPCO
08/03/17
INITIATION
Target $53
OPCO
Outperform
Global Blood Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Global Blood Therapeutics with an Outperform and a $53 price target telling investors it is conducting a pivotal trial of GBT440 that has the potential to demonstrate clinical benefits reaching well beyond reduction in vaso-occlusive events in patients with sickle cell disease. With multiple readouts, the analyst believes the company may represent an attractive takeout for a large biopharmaceutical company seeking to expand its footprint in hematologic and/or pulmonary indications.
05/01/17
JANY
05/01/17
INITIATION
Target $37
JANY
Buy
Global Blood Therapeutics initiated with a Buy at Janney Capital
Janney Capital initiated Global Blood Therapeutics with a Buy and a $37 price target.
GEL Genesis Energy
$25.14

-1.24 (-4.70%)

08/07/17
BARD
08/07/17
UPGRADE
BARD
Outperform
Genesis Energy upgraded to Outperform from Neutral at Baird
10/13/17
LEHM
10/13/17
UPGRADE
Target $27
LEHM
Equal Weight
Genesis Energy upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Theresa Chen upgraded Genesis Energy to Equal Weight saying the 31% distribution cut is a "logical move" that puts the partnership on better footing to de-lever and grow the business. The analyst lowered her price target for the shares to $27 from $31.
07/18/17
LEHM
07/18/17
DOWNGRADE
LEHM
Underweight
Genesis Energy downgraded to Underweight from Equal Weight at Barclays
10/13/17
MUFG
10/13/17
NO CHANGE
Target $29
MUFG
Neutral
Genesis Energy price target lowered to $29 from $35 at MUFG
MUFG analyst Barrett Blaschke lowered his price target for Genesis Energy to $29 after the partnership announced a reduction in its distribution rate. The analyst believes the move puts Genesis Energy on "firmer financial footing" and keeps a Neutral rating on the shares.

TODAY'S FREE FLY STORIES

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$265.70

10.31 (4.04%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Huntington Ingalls awarded $1.43B government contract modification »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIT

AMCON Distributing

$87.50

0.13 (0.15%)

17:24
02/16/18
02/16
17:24
02/16/18
17:24
Hot Stocks
Breaking Hot Stocks news story on AMCON Distributing »

Hale Partnership reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.09

-0.76 (-1.82%)

, TSLA

Tesla

$335.49

1.425 (0.43%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Periodicals
Chevy Bolt sales bolstered by Tesla delays, tax credit worries, Reuters says »

Certain potential buyers…

GM

General Motors

$41.09

-0.76 (-1.82%)

TSLA

Tesla

$335.49

1.425 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AGN

Allergan

$164.04

-0.43 (-0.26%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Syndicate
Breaking Syndicate news story on Allergan »

Allergan files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.